SA Factor
John Wiley & Sons
2e druk, 2005
9781405126199
Drug Induced Movement Disorders 2e
Specificaties
Gebonden, 482 blz.
|
Engels
John Wiley & Sons |
2e druk, 2005
ISBN13: 9781405126199
Rubricering
Levertijd ongeveer 8 werkdagen
Samenvatting
An invaluable addition to the library of any neurologist, this book updates and presents the current state of the art clinical approaches to this subject, assisting neurologists and physicians alike in this difficult but increasingly common situation.
Specificaties
ISBN13:9781405126199
Taal:Engels
Bindwijze:gebonden
Aantal pagina's:482
Uitgever:John Wiley & Sons
Druk:2
Inhoudsopgave
Section 1: General Considerations.
<p>Chapter 1: Movement Disorders: Approach, Definitions and differential Diagnosis.</p>
<p>Martin Cloutier, Anthony E. Lang.</p>
<p>Chapter 2: Rating Scales for Movement Disorders.</p>
<p>Wonodi I, Hong EH, Avila MT, Gunvant Thaker.</p>
<p>Chapter 3: Spontaneous movement disorders in psychiatric patients.</p>
<p>Irene Richard, Christopher O Brien, Roger Kurlan.</p>
<p>Section 2: Antipsychotics.</p>
<p>Chapter 4: Pharmacology of typical and atypical agents.</p>
<p>Gary Remington, Shitij Kapur.</p>
<p>Chapter 5: Acute Drug–induced Dystonia.</p>
<p>Michael F. Mazurek, Patricia I. Rosebush.</p>
<p>Chapter 6: Drug–Induced Parkinsonism.</p>
<p>Joseph H. Friedman, Martha E. Trieschmann, Hubert H. Fernandez.</p>
<p>Chapter 7: Acute Akathisia.</p>
<p>Author: Lenard A. Adler, John Rotrosen, Burt Angrist.</p>
<p>Chapter 8: Neuroleptic Malignant Syndrome.</p>
<p>Stewart A. Factor.</p>
<p>Chapter 9: Classical Tardive Dyskinesia.</p>
<p>Thomas M. Hyde, MD, Jose A. Apud, Whitney C. Fisher, Michael F. Egan.</p>
<p>Chapter 10: Tardive dyskinesia Variants.</p>
<p>Skidmore F, Weiner W, Burke R.</p>
<p>Chapter 11: Movement Disorders caused by atypical antipsychotics.</p>
<p>Karen E. Anderson.</p>
<p>Chapter 12: Commentary: Is Tardive dyskinesia disappearing?James Lohr, MD.</p>
<p>.</p>
<p>.</p>
<p>Section 3: Dopaminomimetic Drugs.</p>
<p>Chapter 13: Dyskinesia induced by levodopa and dopamine agonists in Parkinson s disease.</p>
<p>John G. Nutt, Matthew Brodsky.</p>
<p>Chapter 14: Stimulant Drugs.</p>
<p>Anthony E. Munson, Juan Sanchez–Ramos, William J Weiner.</p>
<p>Section 5: Other Drugs.</p>
<p>Chapter 15: Antidepressants.</p>
<p>Marie L. Moro–de–Casillas, David E. Riley.</p>
<p>Chapter 16: Anticonvulsants.</p>
<p>John C. Morgan, Madeline Harrison.</p>
<p>Chapter 17: Miscellaneous Drugs.</p>
<p>Daniel Tarsy</p>
<p>Chapter 1: Movement Disorders: Approach, Definitions and differential Diagnosis.</p>
<p>Martin Cloutier, Anthony E. Lang.</p>
<p>Chapter 2: Rating Scales for Movement Disorders.</p>
<p>Wonodi I, Hong EH, Avila MT, Gunvant Thaker.</p>
<p>Chapter 3: Spontaneous movement disorders in psychiatric patients.</p>
<p>Irene Richard, Christopher O Brien, Roger Kurlan.</p>
<p>Section 2: Antipsychotics.</p>
<p>Chapter 4: Pharmacology of typical and atypical agents.</p>
<p>Gary Remington, Shitij Kapur.</p>
<p>Chapter 5: Acute Drug–induced Dystonia.</p>
<p>Michael F. Mazurek, Patricia I. Rosebush.</p>
<p>Chapter 6: Drug–Induced Parkinsonism.</p>
<p>Joseph H. Friedman, Martha E. Trieschmann, Hubert H. Fernandez.</p>
<p>Chapter 7: Acute Akathisia.</p>
<p>Author: Lenard A. Adler, John Rotrosen, Burt Angrist.</p>
<p>Chapter 8: Neuroleptic Malignant Syndrome.</p>
<p>Stewart A. Factor.</p>
<p>Chapter 9: Classical Tardive Dyskinesia.</p>
<p>Thomas M. Hyde, MD, Jose A. Apud, Whitney C. Fisher, Michael F. Egan.</p>
<p>Chapter 10: Tardive dyskinesia Variants.</p>
<p>Skidmore F, Weiner W, Burke R.</p>
<p>Chapter 11: Movement Disorders caused by atypical antipsychotics.</p>
<p>Karen E. Anderson.</p>
<p>Chapter 12: Commentary: Is Tardive dyskinesia disappearing?James Lohr, MD.</p>
<p>.</p>
<p>.</p>
<p>Section 3: Dopaminomimetic Drugs.</p>
<p>Chapter 13: Dyskinesia induced by levodopa and dopamine agonists in Parkinson s disease.</p>
<p>John G. Nutt, Matthew Brodsky.</p>
<p>Chapter 14: Stimulant Drugs.</p>
<p>Anthony E. Munson, Juan Sanchez–Ramos, William J Weiner.</p>
<p>Section 5: Other Drugs.</p>
<p>Chapter 15: Antidepressants.</p>
<p>Marie L. Moro–de–Casillas, David E. Riley.</p>
<p>Chapter 16: Anticonvulsants.</p>
<p>John C. Morgan, Madeline Harrison.</p>
<p>Chapter 17: Miscellaneous Drugs.</p>
<p>Daniel Tarsy</p>